Introduction
============

Pancreatic cancer is a severe disease with a poor 5-year survival rate of \<5% ([@b1-ol-0-0-8732]--[@b3-ol-0-0-8732]). Despite the great strides made in the surgical and chemotherapeutic management of pancreatic cancer, the disease continues to have a poor prognosis. Pancreatic cancer has an unfavourable outcome because it is difficult to detect at early stages. Patients are typically diagnosed at a late stage when the cancer has already locally advanced or spread to other parts of the body ([@b4-ol-0-0-8732]--[@b7-ol-0-0-8732]). The only potentially curative therapy is surgical resection. However, when patients are diagnosed with pancreatic cancer, more than half are at an unresectable stage and are given chemotherapy, radiation, palliative surgery or supportive care ([@b8-ol-0-0-8732],[@b9-ol-0-0-8732]). Even if patients undergo curative resection, their 5-year survival rates are approximately 15--20%, with a median survival of 16 to 23 months ([@b10-ol-0-0-8732]--[@b13-ol-0-0-8732]).

Peritoneal metastasis is one of the most important prognostic factors for pancreatic cancer. According to the National Comprehensive Cancer Network (NCCN), the presence of peritoneal metastasis is an inoperative factor for pancreatic cancer ([@b14-ol-0-0-8732]).

Radical surgery is chosen among options including pancreaticoduodenectomy (PD), distal pancreatectomy (DP) or total pancreatectomy, according to the location of the pancreatic cancer. These operations are relatively invasive surgeries ([@b15-ol-0-0-8732]--[@b17-ol-0-0-8732]).

It is important to diagnose peritoneal metastasis to avoid unnecessary laparotomy and to determine the appropriate therapy. However, it is difficult to detect small nodules suspected to be peritoneal metastasis during pre-operative imaging examinations, through techniques such as computed tomography (CT) and ^18^F-fluoro-deoxy-glucose positron emission tomography (FDG-PET). Small lesions can be diagnosed only by intra-operative findings ([@b9-ol-0-0-8732],[@b18-ol-0-0-8732]). Despite the availability of high-resolution CT scans, occult distant metastases are still observed in 11% of patients during surgery ([@b18-ol-0-0-8732]).

Sugiura *et al* have identified recurrent disease (at the local, lymph node, peritoneum, liver and other distant levels) in 76.9% of pancreatic cancer patients with an R0-resection (curative resection with a negative pathologic margin) ([@b19-ol-0-0-8732]). In Helsinki University Hospital, in a subgroup of patients with T1-2 disease and an N0 \[the Tumour-Node-Metastasis (TNM) classification of the Union for International Cancer Control (UICC)\] or R0-resection, the 5-year survival was 49%, and the 10-year survival was 31% ([@b17-ol-0-0-8732]). Even after an R0-resection, some few patients died from recurrence ([@b12-ol-0-0-8732],[@b17-ol-0-0-8732],[@b19-ol-0-0-8732],[@b20-ol-0-0-8732]). In the R0-resection patient group, the partial cause of recurrence might be the difficulty of intraoperative assessment of small or flat peritoneal metastases. It is necessary to be more precise in detecting peritoneal metastases by intra-operative findings.

Staging laparoscopy has been proposed as a minimally invasive technique to detect radiographically occult intraperitoneal metastatic lesions ([@b18-ol-0-0-8732],[@b21-ol-0-0-8732]--[@b24-ol-0-0-8732]). However, diagnosis with standard laparoscopy has limitations. Schnelldorfer *et al* have reported that standard laparoscopy misses the majority of these metastases, thus resulting in a substantial number of patients undergoing a nontherapeutic laparotomy ([@b18-ol-0-0-8732]).

5-aminolevulinic acid (5-ALA) is a natural amino acid that is metabolized into photosensitive protoporphyrin IX (PpIX), which accumulates in cancer cells. PpIX emits red (peak wavelength \~635 nm) fluorescence when it is excited with blue light (peak wavelength \~405 nm), and the fluorescence diagnosis of cancer by using this property is called photodynamic diagnosis (PDD) ([@b25-ol-0-0-8732],[@b26-ol-0-0-8732]). Recently, researchers have reported the usefulness of PDD using 5-ALA (5-ALA-PDD) in the fields of neurosurgery and urology ([@b27-ol-0-0-8732]--[@b30-ol-0-0-8732]). Fluorescence cystoscopy has a sensitivity for detection of bladder lesions of 94.2% and a specificity of 80.0% ([@b27-ol-0-0-8732]). We have previously reported the use of 5-ALA-PDD for detection of peritoneal dissemination and lymph node metastasis in patients with gastric or colorectal cancer ([@b31-ol-0-0-8732]--[@b36-ol-0-0-8732]).

In the present study, we evaluated the usefulness of 5-ALA-PDD for detecting peritoneal metastasis of pancreatic cancer during staging laparoscopy.

Materials and methods
=====================

### Cell line and culture

The human pancreatic adenocarcinoma cell line AsPC-1 (Wako Pure Chemical Industries, Ltd., Osaka, Japan), which was engineered to stably express green fluorescent protein (GFP), was used. AsPC-1-GFP was cultured in RPMI-1640 medium supplemented with 10% foetal bovine serum and 1% penicillin/streptomycin in tissue culture dishes humidified at 37°C in an atmosphere of 95% air and 5% carbon dioxide.

### In vitro experiments

AsPC-1-GFP (1×10^6^ cells) cells were cultured for 3 days. Dishes were washed with PBS and incubated with RPMI-1640 medium with 1 mM 5-ALA hydrochloride (Wako Pure Chemical Industries) for 3 h. Then, we observed the fluorescence of PpIX (excitation, 440 nm; emission, 575--675 nm) and GFP (excitation, 488 nm; emission, 500--560 nm) with an inverted microscope (IX81) equipped with a confocal scanning system (FV1000; both Olympus, Tokyo, Japan).

### Animals

Five-week-old-female BALB/c nude mice were used in this study. All *in vivo* experiments were approved and followed the institutional guidelines of the Kyoto Prefectural University of Medicine (Kyoto, Japan). The mice were housed in plastic cages with stainless steel grid tops in an air-conditioned environment with a 12-h light-dark cycle and had access to food and water *ad libitum*.

### Establishment of the mouse model of peritoneal metastasis and fluorescence observation

An aliquot of 5×10^6^ AsPC-1-GFP cells was injected into the peritoneal cavities of mice under general anaesthesia. After 3 weeks, the mice were intraperitoneally injected with 5-ALA hydrochloride at a dose of 250 mg/kg body weight. Four h after 5-ALA administration, the mice were euthanized, and laparotomy was performed ([@b37-ol-0-0-8732]). Fluorescence observation was performed with a stereoscopic microscope (SZX16; Olympus) equipped with a colour charge-coupled digital camera (DP73) and a mercury lamp (U-LH100HG; both Olympus). PpIX images (\>430 nm; HQ430LP) were acquired by excitation at 405±20 nm (D405/20×; both Chroma Technology Corp., Rockingham, VT, USA), and GFP fluorescence images (595--540 nm; GFPHQ cube) were acquired by excitation at 460 to 480 nm (GFPHQ cube, both Olympus). The merged image composites were generated with image analysis software (ImageJ 1.45s, National Institutes of Health, Bethesda, MD, USA).

### Enrolled patients

Thirty-two patients clinically diagnosed with pancreatic cancer and 2 patients clinically diagnosed with intraductal papillary-mucinous carcinoma (IPMC) were enrolled in the present study. They underwent surgery at the University Hospital, Kyoto Prefectural University of Medicine, between April 2013 and February 2016. Peritoneal metastasis was not detected by pre-operative imaging examinations, such as CT and FDG-PET.

The present study was approved by the Ethics Committee of Kyoto Prefectural University of Medicine, Kyoto, Japan. The patients provided signed informed consent pre-operatively.

### Laparoscopic procedure

5-ALA hydrochloride (Cosmo Bio Co., Ltd., Tokyo, Japan) was orally administered to patients 3 h before surgery at a dose of 20 mg per kg body weight (≤1 g per individual) ([@b36-ol-0-0-8732],[@b37-ol-0-0-8732]). The system used to perform fluorescence laparoscopy in 3 patients was previously described ([@b31-ol-0-0-8732]). Thirty-one patients were observed with a D-LIGHT C system (Karl Storz GmbH & Co., Tuttlingen, Germany).

At the beginning of the staging laparoscopy, the abdominal cavity was observed under white light and fluorescence imaging with a long pass filter (\>450 nm); images were obtained under excitation with blue light (380--430 nm).

Results
=======

### Stereomicroscopic imaging analyses of pancreatic cancer cell lines in vitro

As shown in [Fig. 1](#f1-ol-0-0-8732){ref-type="fig"}, PpIX-induced red fluorescence was observed in the ASPC-1-GFP cells treated with 1 mM 5-ALA hydrochloride. The PpIX-induced red fluorescence matched the observed GFP-induced green fluorescence. These results indicated that PpIX had accumulated in the human pancreatic cancer cells treated with 5-ALA.

### Stereomicroscopic imaging analyses of peritoneal metastasis in a mouse model

To determine whether 5-ALA administration can be used to specifically visualize peritoneal metastasis, a mouse model of peritoneal metastasis was used. Three weeks after intraperitoneal injection of ASPC-1-GFP cells, the peritoneal metastases at the mesentery were visible macroscopically. Although detection of the small nodules of the mesentery was difficult under white light conditions, the small nodules were easily identified in the fluorescence images. The 5-ALA-induced red fluorescent nodules matched the observed GFP-induced green fluorescent nodules ([Fig. 2](#f2-ol-0-0-8732){ref-type="fig"}). In our study, peritoneal inspection was performed by counting the nodules by using the same size field of view of the mesentery in five mice ([Fig. 3](#f3-ol-0-0-8732){ref-type="fig"}). In the five mice examined, the tumor detection rate using ALA-PDD was higher than that for white light observation (100%; 184/184 vs. 21.2%; 39/184).

### Laparoscopic 5-ALA-PDD of peritoneal metastasis in pancreatic cancer patients

The details of the patient characteristics are summarized in [Tables I](#tI-ol-0-0-8732){ref-type="table"} and [II](#tII-ol-0-0-8732){ref-type="table"}. The patients comprised 19 men and 15 women (median age, 70.5 years; range, 39--81 years) who had been clinically diagnosed with Stage IA-III pancreatic cancer or IPMC (UICC 6th TNM classification). All patients underwent conventional staging laparoscopy and fluorescent observation. In 9 patients, peritoneal nodules suspected to be peritoneal metastasis were observed under white light. In 4 (case 1, 15, 29 and 34) of the 9 patients, nodules were detected in the fluorescence images. All nodules were pathologically diagnosed as peritoneal metastasis ([Fig. 4](#f4-ol-0-0-8732){ref-type="fig"}). In the other five cases (case 4, 25, 26, 28 and 33), the nodules that were observed under white light but not under fluorescence excitation were diagnosed as non-malignant by frozen section diagnosis ([Fig. 5](#f5-ol-0-0-8732){ref-type="fig"}). The pathological results for cases 4 and 28 indicated fibroadipose tissue. Similarly, the results for case 25 indicated fibrosis tissue, those for case 26 indicated collagen fibre, and those for case 33 indicated fat and blood vessels.

Four patients (case 9, 11, 14 and 32) were diagnosed with borderline resectable pancreatic cancer by clinical examination and underwent a preoperative staging laparoscopy. These patients did not have inoperative factors and would have been administered neoadjuvant therapy ([@b38-ol-0-0-8732]). In 5 patients (cases 1, 10, 15, 29 and 34), palliative procedures or an exploratory laparotomy were used because unresectable factors existed ([@b38-ol-0-0-8732]). In 2 patients (cases 3 and 30), the pathological diagnosis was chronic pancreatitis. No false positives or false negatives were observed in these experiments. None of the enrolled patients experienced any side effects due to 5-ALA hydrochloride administration.

Discussion
==========

Pancreatic cancer has one of the poorest prognoses of any cancer ([@b1-ol-0-0-8732]--[@b3-ol-0-0-8732]). Radical surgery is very invasive ([@b15-ol-0-0-8732]--[@b17-ol-0-0-8732]). It is important to diagnose peritoneal metastasis to determine the appropriate therapy and to avoid nontherapeutic laparotomy. However, detection of small nodules suspected to be peritoneal metastases by pre-operative imaging examinations, such as CT and FDG-PET, is difficult ([@b9-ol-0-0-8732],[@b18-ol-0-0-8732]).

The use of diagnostic laparoscopy for pretherapeutic staging of intraperitoneal tumours has been steadily increasing ([@b18-ol-0-0-8732],[@b22-ol-0-0-8732]--[@b24-ol-0-0-8732]). The benefits of preoperative staging laparoscopy have been reported for borderline resectable pancreatic cancer ([@b38-ol-0-0-8732],[@b39-ol-0-0-8732]). The complication rate of the staging laparoscopy is very low ([@b24-ol-0-0-8732]). No acute major complications were found in this study. A major complication that can occur because of treatment delays is the development of port-site metastasis, which has been reported in up to 1% of diagnostic staging laparoscopies, thus suggesting that this is an uncommon complication ([@b24-ol-0-0-8732],[@b40-ol-0-0-8732]--[@b42-ol-0-0-8732]).

Preoperative staging laparoscopy reveals peritoneal and superficial liver metastasis in \~25% of cases and therefore helps to avoid unnecessary laparotomies. However, unresectable tumours are found in open laparotomy after a staging laparoscopy in 12% of cases. In an additional 6.8% of cases, peritoneal metastases are completely missed during the staging laparoscopy ([@b21-ol-0-0-8732],[@b23-ol-0-0-8732],[@b24-ol-0-0-8732]).

Recently, researchers have reported the utility of 5-ALA-PDD in the fields of neurosurgery and urology ([@b27-ol-0-0-8732]--[@b30-ol-0-0-8732]). 5-ALA has few side effects and is a safe drug that has previously been used to diagnose glioma and bladder cancer ([@b27-ol-0-0-8732]--[@b30-ol-0-0-8732]). Although 5-ALA-PDD is a useful method, only a few reports have examined the use 5-ALA-PDD for the diagnosis of peritoneal metastasis in human intra-abdominal malignancy ([@b23-ol-0-0-8732],[@b24-ol-0-0-8732],[@b36-ol-0-0-8732],[@b43-ol-0-0-8732]). Gahlen *et al* have reported that the use of fluorescence laparoscopy increases the visualization of intraperitoneal tumours by 17.5%, as compared with white light laparoscopy ([@b23-ol-0-0-8732]). To our knowledge, the present study is the first systematic report of the use of 5-ALA-PDD during staging laparoscopy for detection of peritoneal metastasis of pancreatic cancer. Our results suggest that the use of this method is applicable for the detection of peritoneal metastasis of pancreatic cancer in real time, which should improve the diagnostic accuracy of peritoneal metastasis.

The 5-ALA-PDD method has some disadvantages. A weak point of this technique is that deep observations are not possible because the penetration of blue light is low in tissues ([@b32-ol-0-0-8732],[@b43-ol-0-0-8732]). Another problem is the undesirable effect of physiological accumulation of PpIX and autofluorescence of the surrounding tissues ([@b36-ol-0-0-8732]). 5-ALA hydrochloride is administered orally. Therefore, this drug is problematic for patients with symptoms due to gastroduodenal obstruction, such as nausea, vomiting, and difficulty with oral intake. Patients with pancreatic malignancies have a 13--20% risk of duodenal stenosis ([@b44-ol-0-0-8732]).

We were not able to experience the persuasive case that is difficult to recognize peritoneal metastasis under white light but easy to recognize under fluorescent observation. We showed that the all nodules suspected of peritoneal metastasis and diagnosed as malignant histopathologically can be identified by the fluorescent observation in realtime. False positive and false negative cases were not observed in our study but would be inevitable if the case series were increased. Negative proof, such as the absence of false negatives, is difficult to provide. Gahlen *et al* have suggested that open visual inspection and palpation of the entire peritoneal surface are necessary to exclude false negatives; however, it is almost impossible to examine the entire peritoneal surface histopathologically ([@b23-ol-0-0-8732]). The prognosis should be continuously followed-up.

In the present study, we demonstrated the presence of PpIX-induced red fluorescence in pancreatic cells *in vitro* and *in vivo*. In our human study, we observed red fluorescence in peritoneal metastasis of pancreatic cancer by using 5-ALA-PDD during staging laparoscopy. This study indicates that 5-ALA-PDD is useful for detecting peritoneal metastasis during staging laparoscopy in human pancreatic cancer patients.

In conclusion, we confirmed that the use of 5-ALA-PDD during staging laparoscopy is promising for the rapid diagnosis of peritoneal metastasis in pancreatic cancer patients. We suggest that future research assessing the clinical usefulness of this method would be worthwhile.
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![Stereomicroscopic imaging analyses of the human pancreatic cancer cell line AsPC-1-GFP *in vitro*. (A and D) Imaging under white light, (B and E) fluorescence excitation (excitation, 440 nm; emission, 575--675 nm) and (C and F) excitation, 488 nm; emission, 500--560 nm. Scale bar, 50 µm. 5-ALA-PDD, 5-aminolevulinic acid.](ol-16-01-0821-g00){#f1-ol-0-0-8732}

![Stereomicroscopic imaging analyses of peritoneal metastasis at the mesentery in a mouse model. (A) Imaging under white light and (B) fluorescence excitation (excitation, 440 nm; emission, 575--675 nm) (C) excitation, 468--480 nm; emission, 495--540 nm. The merged image was generated by ImageJ. (D) Scale bar, 5 mm.](ol-16-01-0821-g01){#f2-ol-0-0-8732}

![An example of peritoneal metastasis nodules of the mesentery in a mouse. Imaging under white light (left), green fluorescence of green fluorescent protein (middle) and red fluorescence of protoporphyrin IX (right). Recognizable tumor nodules under white light are marked (→). In this case, the tumor detection rate under the white light condition was 52.6% (10/19), and that of ALA-PDD was 100% (19/19). Scale bar, 5 mm. ALA-PDD, photodynamic diagnosis using 5-ALA-PDD.](ol-16-01-0821-g02){#f3-ol-0-0-8732}

![Laparoscopic images of (A and B) case 1 and (C and D) case 15. (A and C) The nodules of the peritoneum under white light conditions. (B and D) Visible red fluorescence under fluorescence light.](ol-16-01-0821-g03){#f4-ol-0-0-8732}

![Laparoscopic images of (A and B) case 4 and (C and D) case 25. (A and C) Nodules of the peritoneum under white light conditions. (B and D) Red fluorescence did not appear under fluorescence excitation.](ol-16-01-0821-g04){#f5-ol-0-0-8732}

###### 

Patient characteristics (n=34).

  Characteristic                                                  Number of patients
  --------------------------------------------------------------- --------------------
  Sex                                                             
    Male                                                          19
    Female                                                        15
  Age range (median), years                                       39--81 (70.5)
  Cancer TNM stage^[a](#tfn1-ol-0-0-8732){ref-type="table-fn"}^   
    0                                                             0
    IA                                                            2
    IB                                                            2
    IIA                                                           24
    IIB                                                           2
    III                                                           4
    IV                                                            0

UICC 6th TNM classification. UICC, Union for International Cancer Control; TNM, tumour, node and metastasis.

###### 

Patient characteristics and comparison of the detection of peritoneal metastases under white light and fluorescence excitation.

                                                              Peritoneal assessment        
  ---- ------ -------- ----------------- -------------------- ----------------------- ---- ----
  1    PK     UR                         T4N0M0 Stage III/    \+                      \+   Pm
                                         T4N0M1 Stage IV                                   
  2    PK     PH       Lm                T3N0M0 Stage IIA/                            −    
                                         T3N0M1 Stage IV                                   
  3    PK     DP       CP                T2N0M0 Stage IIA/−                           −    
  4    PK     PD       IDC               T3N0M0 Stage IIA/    \+                      −    −
                                         T3N1M0 Stage IIB                                  
  5    PK     PD       IPMC (invasive)   TN0M0 Stage IIA/                             −    
                                         T3N0M0 Stage IIA                                  
  6    PK     DP       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage IIB                                  
  7    PK     PD       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage II                                   
  8    PK     DP       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N0M0 Stage IIA                                  
  9    PK     SL                         T4N1M0 Stage III/                            −    
                                         T4N1M0 Stage III                                  
  10   PK     UR                         T3N1M0 Stage IIA/                            −    
                                         T4N1M0 Stage III                                  
  11   PK     SL                         T3N0M0 Stage IIA/                            −    
                                         T3N0M0 Stage IIA                                  
  12   PK     PD       IDC               T3N1M0 Stage IIB/                            −    
                                         T3N0M0 Stage IIA                                  
  13   PK     DP       IDC               T4N0M0 Stage II/                             −    
                                         T3N1M0 Stage IIB                                  
  14   PK     SL                         T3N0M0 Stage IIA/                            −    
                                         T3N0M0 Stage IIA                                  
  15   PK     UR                         T3N0M0 Stage IIA/    \+                      \+   Pm
                                         T3N0M1 Stage IV                                   
  16   PK     DP       *In situ*         T1N0M0 Stage IA/                             −    
                                         TisN0M0 Stage 0                                   
  17   PK     PD       *In situ*         T3N0M0 Stage IIA/                            −    
                                         TisN0M0 Stage 0                                   
  18   PK     DP       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage IIB                                  
  19   IPMC   PD       IPMC              T1N0M0 Stage IA/                             −    
                                         T1N0M0 Stage IA                                   
  20   PK     PD       IPMC (invasive)   T2N0M0 Stage IB/                             −    
                                         T2N0M0 Stage IB                                   
  21   PK     PD       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage IIB                                  
  22   PK     DP, PH   IDC, HCC          T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage IIB                                  
  23   PK     DP       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N1M0 Stage IIB                                  
  24   PK     PD       IDC               T3N1M0 Stage IIB/                            −    
                                         T3N1M0 Stage IIB                                  
  25   PK     DP       IDC               T3N0M0 Stage IIA/    \+                      −    −
                                         T3N1M0 Stage IIB                                  
  26   PK     DP       IDC               T3N0M0 Stage IIA/    \+                      −    −
                                         T3N0M0 Stage IIA                                  
  27   PK     PD       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N0M0 Stage IIA                                  
  28   PK     PD       IDC               T3N0M0 Stage IIA/    \+                      −    −
                                         T3N0M0 Stage IIA                                  
  29   PK     UR                         T3N0M0 Stage IIA/    \+                      \+   Pm
                                         T3N0M1 Stage IV                                   
  30   PK     DP       CP                T3N0M0 Stage IIA/−                           −    
  31   PK     DP       IDC               T3N0M0 Stage IIA/                            −    
                                         T3N0M0 Stage IIA/                                 
  32   PK     SL                         T4N0M0 Stage III/                            −    
                                         T4N0M0 Stage III                                  
  33   IPMC   DP       IPMC (invasive)   T3N0M0 Stage IIA/    \+                      −    −
                                         T3N1M0 Stage IIB                                  
  34   PK     UR                         T3N0M0 Stage IIA/    \+                      \+   Pm
                                         T3N0M1 Stage IV                                   

UICC 6th TNM classification. UICC, Union for International Cancer Control; TNM, tumour, node and metastasis; WL, white light; BL, fluorescence light; PK, pancreatic cancer; SL, staging laparoscopy; PD, pancreaticoduodenectomy; DP, distal pancreatectomy; PH, partial hepatectomy; UR, unresectable; Pm, peritoneal metastasis; Lm, liver metastasis; CP, chronic pancreatitis; IDC, invasive ductal carcinoma; IPMC, intraductal papillary-mucinous carcinoma; *in situ*, adenocarcinoma *in situ*; HCC, hepatocellular carcinoma.
